Search
Close this search box.

IMEXPHARM

Red Capital invested in Imexpharm Pharmaceutical Joint Stock Company (“Imexpharm”) in 2017

Red Capital invested in Imexpharm Pharmaceutical Joint Stock Company ("Imexpharm") in 2017

Red Capital invested in Imexpharm Pharmaceutical Joint Stock Company (“Imexpharm”) in 2017 when Imexpharm invested in its first EU-GMP manufacturing line. Imexpharm has always been a pioneer in producing high-quality pharmaceuticals by proactively adopting European technology in manufacturing since 1999. Currently, the company boasts the largest number of EU-GMP standard production lines in the country, with 11 EU-GMP lines across 3 factory clusters.

The investment in Imexpharm not only brought positive returns to us but also helped Red Capital refine its investment formula in companies with:

  • Visionary leadership focused on owning the key competitive factors/resources/capabilities that determine the success or failure of each business “game” in a competitive and rapidly changing business environment;
  • Advanced, open-minded governance system capable of self-learning and self-training to maintain a leading position;
  • Strong financial health and effective risk management;
  • Continuous improvement of customer trust and confidence in the brand.

Others Investments of ours